Effect of erythromycin on the oro-caecal transit time in man

Lehtola, J; Jauhonen, Pekka; Kesäniemi, Antero; Wikberg, R.; Gordin, A.

doi:10.1007/bf00316094

Cited by 28 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lehtola et al however, assessed orocaecal transit time for liquids only, as no solids were given with the laculose test load. 16 In contrast, Edelbroeck et al reported that an intravenous infusion of erythromycin retards the orocaecal transit of lactulose in healthy male subjects. 12 The results of our present study reflect the orocaecal transit time of a lactulose plus solid meal which is a more physiological situation.…”

Section: Discussionmentioning

confidence: 96%

“…The doses used in our study are similar to those that have been used to effectively treat gastroparesis.61 Lehtola et al studied the effect on orocaecal transit time in normal subjects using doses of 800 mg of erythromycin stearate and 1000 mg of erythromycin acistrate. 16 They showed that erythromycin significantly decreased the orocaecal transit time. Significant adverse gastrointestinal side-effects were also noted, presumably because of the high doses.…”

Section: Discussionmentioning

confidence: 99%

“…Front transit time was recorded as the time point when a sustained rise in breath hydrogen concentration of at least 5 p.p.m. was first observed 16. This represents the front of the meal reaching the caecum.…”

mentioning

confidence: 91%

“…'^^ l5 Lehtola et al investigated the effect of erythromycin on orocaecal transit in healthy humans.16 Gastrointestinal motility is affected by different phases of the menstrual cycle,17 and this factor was not controlled in their study. 16 The present study was designed to study the effect of erythromycin on the orocaecal transit time of a lactulose plus breakfast meal. To our knowledge, it is the first prospective, double-blind, placebo-controlled investigation which examines the effects of two standard doses of orally administered erythromycin on the orocaecal transit of a lactulose with solid meal in male subjects with poorly controlled insulin-requiring diabetes mellitus.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Erythromycin shortens orocaecal transit time in diabetic male subjects : a double‐blind placebo‐controlled study

Minocha

Katragadda

Rahal

et al. 1995

Aliment Pharmacol Ther

View full text Add to dashboard Cite

S U M M A R YBackground: The effects of erythromycin on small bowel motility are controversial. Orocaecal transit time (OCTT) is considered to be a valid measure of small bowel motility. Methods: We studied the effect of erythromycin on OCTT in diabetic male subjects in a double-blind placebo-controIled crossover fashion. After an overnight fast, subjects received erythromycin 500 mg, 250 mg or placebo, on 3 different days. A standard solid meal containing 20 g lactulose was administered 30 min after the erythromycin ingestion. Exhaled breath was collected and hydrogen concentration was assessed over 5 h. Breath hydrogen concentrations for each session were analysed over time by a generalized logistic function generating a sigmoidal curve. Front transit time was recorded as the time point when a sustained rise in breath hydrogen concentration of at least 5 p.p.m. was first observed.Results : The mean f S.E.M. time taken for the front of the meal to reach the caecum was 92.5 9.5, 86.1 k 16.5 and 62.3 f 12.1 min for placebo, erythromycin 250 mg and erythromycin 500 mg, respectively. The OCTT was significantly decreased with erythromycin 500 mg compard to placebo ( P < 0.05). Conclusion: Oral administration of 500 mg erythromycin has prokinetic effect on orocaecal transit in male patients with diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Erythromycin shortens orocaecal transit time in diabetic male subjects : a double‐blind placebo‐controlled study

Minocha

Katragadda

Rahal

et al. 1995

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“… 26 –31 Erythromycin lactobionate, stearate, and ethylsuccinate preparations have all been reported to be effective in this situation 26 , . 28 , 29 , 31 Erythromycin also decreases oro‐caecal transit time in healthy volunteers 32 …”

Section: Actions On the Gastrointestinal Tract In Adult Humansmentioning

confidence: 99%

Erythromycin as a prokinetic agent in infants and children

Curry

Lander²,

Stringer

2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Erythromycin has been used as an antibiotic for more than four decades, but only in the last 10 years have other therapeutic benefits of this agent been exploited. Animal and human studies have demonstrated a prokinetic effect on the gastrointestinal tract at sub‐antimicrobial doses (typically a quarter or less of the antibiotic dose). A limited number of studies have been performed in children to investigate this action. A review of this literature is particularly pertinent given the frequency of clinical problems related to gastrointestinal dysmotility in children and the limited availability of prokinetic agents in paediatric practice, compounded by the recent withdrawal of cisapride. The prokinetic effects of erythromycin have been investigated in infants with dysmotility associated with prematurity, in low birth‐weight infants recovering from abdominal surgery, and in older children with a variety of other gastrointestinal disorders. Only one randomized placebo‐controlled trial has been conducted. All except one of these studies have shown a beneficial effect of erythromycin in either promoting tolerance of enteral feeds or enhancing a measured index of gastrointestinal motility. Erythromycin appears to be equally effective when given orally (as ethylsuccinate or estolate) or intravenously (as lactobionate). Significantly, no serious adverse effects have been reported in studies in which erythromycin has been used for its prokinetic effects, although fatal reactions have followed the intravenous administration of erythromycin to neonates in antibiotic doses.

show abstract

Macrolides in roles beyond antibiotic therapy

Pilot

1994

Journal of British Surgery

View full text Add to dashboard Cite

Erythromycin and other macrolides with a closely related structure are widely used antibiotics. Side-effects related to administration of such drugs are mostly gastrointestinal. The direct effect of erythromycin on gastrointestinal motility was studied; it was found to have a stimulatory effect proximally, on stomach and duodenal motility, with an apparent distal inhibition. Gastric emptying was accelerated by erythromycin via an antroduodenal coordination mechanism, an effect that has proved to be beneficial in surgical and medical conditions in which gastroparesis is a problem. Erythromycin is now used experimentally and clinically; it has been found to accelerate gastric as well as gallbladder emptying and to have an effect on the oesophagus. Analogues of erythromycin have been developed that have potent gastrointestinal activity but little or no antibacterial potential. Macrolides modulate the antibacterial action of neutrophils, with some action on the oxidative burst. Finally, two new macrolide immunosuppressants have been developed that compare favourably with traditional drugs.

show abstract

Effect of erythromycin on the oro-caecal transit time in man

Cited by 28 publications

References 27 publications

Erythromycin shortens orocaecal transit time in diabetic male subjects : a double‐blind placebo‐controlled study

Erythromycin shortens orocaecal transit time in diabetic male subjects : a double‐blind placebo‐controlled study

Erythromycin as a prokinetic agent in infants and children

Macrolides in roles beyond antibiotic therapy

Contact Info

Product

Resources

About